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Psychosis:  
The basics and 
beyond 
Psychotic symptoms are a central feature of several different mental disorders. These disorders include 
schizophrenia as well as delusional, 
brief psychotic, schizophreniform and 
schizoaffective disorders, all of which 
are classified as psychotic disorders.1 
Psychotic symptoms can also occur 
in some mood disorders, including 
depression and bipolar disorder. 
Substances, such as cannabis, and 
medical conditions, such as infections 
or epilepsy, can also cause psychotic 
symptoms.1 Regardless of cause, ongoing psychosis is associated with a high degree of impairment — and now 
ranks as the 19th cause of disability worldwide.2
All psychotic disorders include delusions as a core feature.1 These false beliefs are persistently maintained 
despite the absence of evidence to support them. Hallucinations are another feature of most psychotic 
disorders and involve sensations such as hearing voices or seeing objects that others do not perceive. A meta-
analysis that included more than 1,500 youth with psychosis found that auditory 
hallucinations were the most common symptom that these young people struggled with.3 
Collectively, delusions and hallucinations are often referred to as “positive” symptoms, 
because they have been considered to be “an exaggeration of normal functions.”4 
In contrast, the term “negative” symptoms is commonly used to refer to symptoms that 
represent a loss of typical functioning,4 such as reduced expression of emotions and reduced 
involvement in social and academic activities. (The sidebar on page 6 provides information about using more 
sensitive terms to describe so-called positive and negative symptoms.) Psychosis may also include disorganized 
thinking that impairs communication and disorganized behaviour that interferes with daily living.
What causes psychosis?
Sometimes the cause of psychosis can be clearly identified, for example, when episodes are a result of 
substance use or medical conditions. Yet many questions remain about the other causes of psychotic disorders. 
Researchers have put considerable effort into identifying the causes of schizophrenia, in particular, given its 
lifelong consequences. Current evidence suggests that schizophrenia likely results from complex interactions 
occurring over time among thousands of genes and multiple environmental risk factors — none of which 
cause schizophrenia on their own.5 And while genetics play a big role, it does not play the only role.5 For 
example, having a first-degree relative with schizophrenia increases the risk, yet most people with this disorder 
do not have an affected relative.5 Paradoxes like this have led scientists to look at environmental factors that 
can influence both gene expression and overall development. Prenatal exposure to infections and perinatal 
With effective treatments, youth with psychosis can thrive.
Onset of psychotic 
symptoms or 
disorders is very rare 
prior to the teen years.
ov e r v i e w
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complications such as hypoxia appear to increase risk.5–6 Important risks can also occur later in a young 
person’s development, such as heavy cannabis use.6–7 Overall, schizophrenia likely arises as a result of atypical 
brain development due to multiple genetic changes and environmental risks occurring over time.6 Recent 
data also suggest that schizophrenia is rare in young people — with only 0.1% of 12- to 18-year-olds meeting 
diagnostic criteria for this disorder.8
The importance of early intervention
For psychotic disorders, age of onset typically peaks at 22 years for males and 25 for females. Onset of 
psychotic symptoms or disorders is very rare prior to the teen years,3 yet early symptoms sometimes emerge 
in adolescence.9 Therefore, treatment services for young people with psychosis need to be readily available. 
Intervening early is crucial for youth with psychosis, given the strong association between duration of 
untreated symptoms and poorer short- and long-term outcomes.9
Early psychosis intervention (EPI) programs were created to rapidly treat young people 
with psychosis. In BC, EPI programs were first established in 200010 and there are currently 
53 such programs across the province.11 These programs typically provide young people 
with comprehensive assessment, case management, medication management, support and 
education (including for the family), and treatment for any concurrent mental health concerns.12–13 
EPI programs have garnered international praise as possibly “the most significant development in mental 
health services globally since deinstitutionalization.”9 Research evidence suggests that this enthusiasm is 
warranted. Specifically, a meta-analysis comparing four different EPI programs to standard care found that 
youth receiving EPI were more likely to have significantly reduced psychotic symptoms, less likely to relapse 
(32.5% vs. 51.9%), less likely to be hospitalized (28.1% vs. 42.1%), and less likely to discontinue with 
services (27.0% vs. 40.5%).14
Another important shift involves changing negative perceptions that psychosis automatically has a poor 
prognosis. Instead, it is being recognized that psychosis has a malleable course, a finding that may help to 
reduce the associated stigma for young people who have this mental health problem.15 In the Review article 
that follows, we highlight effective psychosis treatments for young people that confirm these reasons for 
hopefulness.
overv iew
Intervening early is 
crucial for youth with 
psychosis.
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What treatments 
work best?
Youth with psychosis need rapid access to effective treatments. To determine which treatments are 
successful — and which are not — we 
conducted a systematic review. We built 
quality assessment into our inclusion 
criteria, requiring studies to use randomized 
controlled trial (RCT) evaluation methods. 
We then searched for RCTs that included 
young people and were published in the 
past 11 years, coinciding with when we last 
reviewed this topic. We also examined our 
previous Quarterly issue on psychosis to 
identify older studies that met our current 
inclusion criteria. This process enabled us to 
address the best RCT evidence from the past 16 years. (Please see the Methods section for more details.)
We retrieved and evaluated 42 studies. In addition to accepting double-blinded placebo-controlled 
medication RCTs, we also accepted head-to-head medication trials if there was previous evidence of 
effectiveness for either medication from placebo-controlled RCTs. (Head-to-head trials directly compare  
the effectiveness of two medications without using a placebo control.) For psychosocial evaluations, we 
accepted comparison groups including treatment as usual or active control groups (e.g., support only).  
Eight RCTs met our inclusion criteria. 
Five of these RCTs evaluated five different medications: aripiprazole (brand name Abilify; two RCTs, 
including one head-to-head trial);16–17 clozapine (brand name Clozaril);18 lurasidone (brand name Latuda);19 
olanzapine (brand name Zyprexa; two RCTs, 
including one head-to-head trial);18, 20 and quetiapine 
(brand name Seroquel).17 Four of the five medication 
studies reported that study authors had ties to 
the pharmaceutical companies that manufactured 
the medications, including some being company 
employees.16–17, 19–20 As well, lurasidone manufacturers 
were involved in study design, data collection and 
analysis, and writing of the manuscript.19 (One older 
study did not report on conflicts of interest.)18
The remaining three RCTs assessed psychosocial 
interventions, namely Cognitive Remediation 
Therapy,21 Computer-Assisted Cognitive 
Remediation,22 and the Think Program.23–24 No 
authors involved in these studies declared any 
conflicts of interest. (We outline another potential 
concern, publication bias, in the sidebar.)
r e v i e w
Quick access to effective treatments helps youth to flourish.
Positive publication bias in intervention trials
I
ntervention evaluations with significant positive findings are 
more likely to be submitted and accepted for academic 
publication than those with null or negative findings — a well-
known phenomenon known as publication bias.
30–32
 In addition 
to wasting research resources when negative results do not 
come to light, this form of bias can mislead policy-makers 
and practitioners, potentially causing considerable harm to the 
health of children. For example, if an intervention has proven 
to be ineffective, or even harmful, but that result is not shared, 
policy-makers and practitioners may continue offering unhelpful 
approaches. Researchers in turn cannot include unreported 
negative findings, for example, when they conduct systematic 
reviews, which involve synthesizing findings from multiple 
studies — resulting in very different and possibly misleading 
conclusions and recommendations. These issues have led to calls 
for all researchers to fulfill their ethical obligation to fully share 
findings from their studies, whether negative or positive. 
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Placebo-controlled medication studies 
The three RCTs using placebo controls evaluated aripiprazole,16 lurasidone19 and olanzapine.20 These three 
RCTs evaluated responses in youth with schizophrenia for six weeks (only). Table 1 provides more details 
about these studies. 
rev iew
 
Table 1: Placebo-Controlled Medication Studies
Ages (years) 
(countries)
13 –17  
(United States + other countries in Europe, 
Africa, South American, Asia + the Caribbean)
13 –17  
(United States, Ukraine, Russia, Bulgaria, 
Romania, Colombia, Mexico, Poland, Philippines, 
Korea, Malaysia, Spain, France + Hungary)
13 –17  











10 mg/day** or 30 mg/day** 
over 6 weeks  
40 mg/day or 80 mg/day** 
over 6 weeks 
 
10 mg/day** to 20 mg/day** 
over 6 weeks  













* Doses are not comparable or equivalent across different medications.
** Youth were started on a lower medication dose, which was titrated up to this final daily dose.    
 
What did placebo-controlled medication studies find?
Aripiprazole resulted in statistically significant benefits at daily doses of both 10 mg and 30 mg — namely, 
higher remission rates at six weeks.16 (Remission was defined as having no more than mild scores on eight 
psychosis symptoms.) Specifically, 57.7% of youth on aripiprazole achieved remission on 30 mg daily, as did 
53.5% on 10 mg, compared to only 35.7% of controls.16 Youth on either dose also had significantly fewer 
“positive” symptoms, such as delusions or hallucinations, and had better overall functioning and quality 
of life.16 But neither dose of aripiprazole significantly reduced “negative” symptoms, such as emotional 
withdrawal.
Aripiprazole also led to adverse events. The most frequent problems were extrapyramidal symptoms such 
as changes in muscle tone and movement difficulties, drowsiness and tremors. These adverse events were worse 
with daily doses of 30 mg than with 10 mg.16 
Lurasidone also led to statistically significant benefits at daily doses of both 40 mg and 80 mg at 
six weeks.19 Specifically, more youth on lurasidone achieved treatment response, defined as psychotic 
symptoms being reduced by 20.0% or more. Overall, 65.1% had this response on the 80 mg dose, as did 
63.9% on 40 mg, compared to only 42% of controls. As well, youth on lurasidone had significantly fewer 
psychotic symptoms, with medium effect sizes for both 
doses (Cohen’s d = 0.48 for 80 mg and 0.51 for 40 mg). 
The medication also led to significantly better overall 
functioning, again with medium effect sizes for both doses 
(d = 0.45 for 80 mg and 0.49 for 40 mg). But lurasidone 
failed to outperform placebo for remission from psychosis 
by six weeks (defined as having no more than mild scores 
on eight psychosis symptoms).19 Lurasidone, too, led to 
adverse events. The most frequent problems were nausea, 
restlessness, vomiting and extrapyramidal symptoms.19
Olanzapine also resulted in statistically significant 
benefits at daily doses of both 10 mg and 20 mg.20 
Conveying respect by choosing words wisely
F
or practitioners and researchers, using phrases such 
as “positive” symptoms to describe delusions and 
hallucinations and “negative” symptoms to describe 
difficulties in engaging may seem like a helpful shortcut. 
But for youth with schizophrenia and their families, this 
phrasing may be unhelpful. Difficult and often frightening 
experiences with delusions and hallucinations may feel far 
from positive; and negatively labelling a youth’s difficulties 
with engagement may contribute to stigma. So phrases such 
as “positive” and “negative” symptoms need to be replaced 
by more sensitive language — preferably chosen by youth 
themselves.
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Specifically, youth on olanzapine had fewer overall psychotic symptoms and fewer “positive” symptoms, 
with a medium effect size for both. But olanzapine made no difference for “negative” symptoms or for 
treatment response rates (defined as overall symptom reductions of 30% or more by end of treatment, and 
as functioning being no more than “mildly ill”).20 Olanzapine also produced benefits beyond addressing 
psychosis, including fewer overall mental health symptoms and less physical aggression toward others. 
As with aripiprazole and lurasidone, olanzapine also led to adverse events.20 The most frequent problems 
were high prolactin levels (which can cause breast milk production in both sexes and impotence in males), 
weight gain, drowsiness, headaches, increased appetite, sedation, dizziness, high levels of alanine transaminase 
(which reflect changes in liver functioning), and changes in triglyceride levels (which are associated with 




treatment options for 




Table 2: Placebo-Controlled Medication Study Outcomes
Outcomes at post-testMedication  
(brand name)
 or  Statistically significant improvements for medication over placebo.
   No statistically significant difference between medication and placebo.
*  Please see the sidebar on page 6 for information about using more sensitive terms to describe these outcomes.
10 mg daily dose
 Psychosis remission
  Overall psychotic symptoms
	Positive psychotic symptoms*
  Negative psychotic symptoms* 
 Overall functioning (3 of 3)
 Overall quality of life
40 mg or 80 mg daily dose
 Treatment response rate
  Psychosis remission
	Overall psychotic symptoms 
 Overall functioning
10 mg to 20 mg daily
  Treatment response rate 
	Overall psychotic symptoms
	Positive psychotic symptoms*
  Negative psychotic symptoms*
	Other mental disorder symptoms (2 of 2) 

















30 mg daily dose 
 Psychosis remission 
	Overall psychotic symptoms 
	Positive psychotic symptoms* 
  Negative psychotic symptoms* 
 Overall functioning (3 of 3) 
 Overall quality of life
  
Head-to-head medication comparison trials
We also included head-to-head trials when one of the medications had already shown benefits in a double-
blinded placebo-controlled RCT. We accepted two such evaluations. One compared aripiprazole and 
quetiapine,17 and one compared olanzapine and clozapine.18
In the study comparing aripiprazole and quetiapine, participating youth had psychotic 
symptoms due to schizophrenia, or delusional, schizoaffective or mood disorders.17 
(Quetiapine was extended release.) Youth received either medication for 12 weeks. 
In the study comparing olanzapine and clozapine, young people participating had 
been diagnosed with schizophrenia before age 13, and they had persistent symptoms and 
impairment despite being tried on at least two other antipsychotic medications.18 Young 
people received either olanzapine or clozapine for eight weeks. All participants also received 
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up to four hours per day of specialized education, recreational and occupational therapy, and nursing care.18 
Table 3 gives more details about these studies.
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20 mg/day** over 12 weeks 
600 mg/day** over 12 weeks
150–500 mg/day over 8 weeks









* Youth were started on a lower medication dose, which was titrated up to the reported final daily dose; doses are 
not comparable or equivalent across different medications.
** Doses could be raised to 30 mg and 800 mg for aripiprazole and quetiapine, respectively, if clinically indicated. 
  
What did head-to-head medication comparison studies find?
The study comparing aripiprazole and quetiapine found that both medications led to significant reductions in 
“positive” symptoms, with no meaningful difference between the medications.17 (Positive symptoms assessed 
included delusions and hallucinations.)
The two medications did yield significant differences in adverse events. Youth on aripiprazole experienced 
extrapyramidal symptoms, restlessness, reduced sleep, increased salivation, nausea, photosensitivity, weight 
loss and cognitive difficulties at higher rates than youth on quetiapine. In contrast, youth on quetiapine 
experienced insulin resistance, difficulties concentrating, increased sleep, emotional indifference, reduced 
salivation, nosebleeds, infections and weight gain (6.4 kg vs. 1.8 kg) at higher rates than youth on 
aripiprazole.17 In addition, more than two-thirds of youth on both medications experienced tremor, dizziness, 
depression, tension and memory difficulties. Notably, 12.1% of youth discontinued aripiprazole due to 
adverse events, versus only 5.5% for quetiapine.17
The other head-to-head trial found one outcome favouring clozapine over olanzapine.18 
After eight weeks, clozapine produced significantly greater reductions in “negative” 
symptoms than olanzapine (Cohen’s d = 0.8). Still, both medications led to benefits 
regarding symptoms and functioning compared with no medication. Both resulted in fewer 
overall psychotic symptoms, fewer negative symptoms and fewer symptoms of mental 
disorders generally, with all but one outcome having a large effect size. However, only 
clozapine reduced “positive” symptoms and improved overall functioning with large effect sizes after eight 
weeks (Cohen’s d = 1.0 and 1.4, respectively).18
Regarding adverse events, both clozapine and olanzapine resulted in marked increases in weight (4 kg 
in eight weeks) and body mass index.18 But clozapine led to significantly more adverse events overall than 
olanzapine, including hypertension and higher resting heart rates, both of which can increase risk for 
cardiovascular disease. Study authors also tracked side effects for 18 of the 25 original participants for two 
years after the trial ended. By that time, eight additional youth were prescribed clozapine because they had 
not improved on olanzapine. At the two-year point, clozapine’s profile was particularly concerning, with 
one participant having extreme weight gain, one developing seizures needing anticonvulsant treatment, and 
Antipsychotics are a 
mainstay in treating 
psychosis in young 
people.
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Some youth with 
psychosis may benefit 
from psychosocial 
interventions.
six developing high cholesterol and/or high triglyceride levels, both of which increase risk for cardiovascular 
disease. Table 4 gives more details on study outcomes.
 
Table 4: Head-to-Head Medication Comparison Study Outcomes
Outcomes at post-test 
Favours medication over comparison
Medication 
(brand name)
 or  Statistically significant improvements.
*  Please see the sidebar on page 6 for information about using more sensitive terms to describe these outcomes.
   No statistically significant difference.
None
None

























	Positive psychotic symptoms* 
	Overall psychotic symptoms
	Positive psychotic symptoms*
	Negative psychotic symptoms* 
 Overall functioning
	Overall mental disorder symptoms 
  Depressive symptoms
  Manic symptoms
  Anxiety symptoms
	Overall psychotic symptoms 
  Positive psychotic symptoms* 
	Negative psychotic symptoms* 
  Overall functioning
	Overall mental disorder symptoms 
  Depressive symptoms
  Manic symptoms
  Anxiety symptoms
 
Improvements at final assessment
  
Including psychosocial interventions for youth with psychosis
All three of the psychosocial interventions were designed to address common concerns for youth with 
psychosis. These concerns included daily life stressors and cognitive challenges associated with their mental 
health condition. 
Cognitive Remediation Therapy aimed to improve cognitive functioning for youth with schizophrenia.21 
The program, delivered in 40 hours over 12 weeks, was designed to improve memory, planning and problem-
solving.21 All study participants were experiencing cognitive and social challenges and had 
been on antipsychotic medication for at least a month. Controls received treatment as 
usual. 
Computer-Assisted Cognitive Remediation similarly aimed to improve cognitive 
functioning, primarily for youth with a psychotic disorder but also for youth assessed as 
being at high risk for psychosis.22 The program, delivered in 12 hours over eight weeks, 
was designed to improve attention, memory and logical thinking. All study participants were experiencing 
challenges, such as memory and attention difficulties, and most (56.3%) were taking antipsychotic 
medications. Control youth participated in computer games requiring attention and motor skills.22
The third intervention, the Think Program, aimed to help young people manage difficulties with daily 
living due to psychosis and to prevent relapses, by also involving their parents.23 The 20-hour program was 
delivered over nine months. It included three individual sessions for youth and parents, provided separately, 
as well as 12 group sessions for youth and parents, also provided separately. All youth study participants were 
rev iew
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living with a parent.23–24 Almost all youth (96.4%) were also taking antipsychotic medications.23 Control 
youth and parents received support only. Table 5 gives more details about these three interventions.
 


















Youth completed memory, planning + problem-solving 
exercises during 40 individual sessions over 12 weeks
Youth completed memory, attention + logical thinking 
exercises during 16 individual sessions over 8 weeks
Youth + parents separately completed psycho-
educational program focused on problem-solving skills 
during 3 individual sessions + 12 group sessions over 













Psychosocial treatments produced limited benefits
At three-month follow-up, youth who had received Cognitive Remediation Therapy displayed significantly 
better cognitive flexibility than controls, with a medium effect size (Cohen’s d = 0.55).21 But there were no 
differences between the groups for any other outcomes, including overall cognitive functioning, memory, 
planning, social functioning, self-esteem, quality of life or general mental disorder symptoms.21 
By post-test, youth who had completed Computer-Assisted Cognitive Remediation outperformed controls 
on one outcome — visual-spatial skills — with a medium effect size (Cohen’s d = 0.62).22 But there were 
no significant group differences for any other outcomes, including memory, language abilities, attention, 
psychosocial functioning or psychotic symptoms.22
At two-year follow-up, youth who had participated in the Think Program showed one benefit: significantly 
fewer emergency room visits for mental health concerns compared to controls (13% vs. 50%, respectively).24 
Yet there were no significant group differences on any other outcomes, which consisted of psychotic 
symptoms, psychotic diagnoses, hospitalizations (including time in the community until hospitalization was 
Family support is vital for youth experiencing psychosis.
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needed, number of admissions and total days in hospital) and overall functioning.24 Table 6 gives more details 
on study outcomes.
 
Table 6: Psychosocial Treatment Study Outcomes
Follow-upIntervention
   No statistically significant difference between treatment and control participants.
 or  Statistically significant improvements for intervention over control participants.









































  Mental disorder symptoms 
  Quality of life




  Social functioning
  Self-esteem
  Overall psychotic symptoms 
  Positive psychotic symptoms*
  Negative psychotic symptoms*
  General psychotic symptoms
 Visual-spatial skills
  Memory
  Language abilities
  Attention
  Psychosocial functioning (2 of 2)
  Overall psychotic symptoms
  Positive psychotic symptoms*
  Negative psychotic symptoms*
  General psychotic symptoms 
  Psychotic disorder diagnoses 
  Number of mental health hospitalizations 
  Number of days in hospital
  Time until hospitalized 
	Emergency room visits for mental health concerns




Regarding medications for treating youth with psychosis, we found two RCTs for both aripiprazole and 
olanzapine, each suggesting benefits, with aripiprazole leading to greater remission rates. Yet both medications 
also led to adverse events that require close monitoring. The other antipsychotics in our review also led to 
benefits, but these were only shown in one RCT, and all came with adverse events. 
Our review of medications has two concerning implications that should be addressed in future research. 
First, no medication studies in our review were conducted at arm’s length from the drug manufacturers. 
Future studies need to be conducted independently, particularly given the safety profiles of antipsychotics. 
Second, we did not find RCT evidence that met our criteria on risperidone (brand name Risperidal), which 
is commonly prescribed for young people.25 Other researchers have raised concerns about the poor quality 
of trials on risperidone (and other antipsychotics).26 It is therefore important that new trials be conducted to 
expand the evidence on effective medications for treating young people who have psychosis.
Regarding psychosocial interventions, Cognitive Remediation Therapy and Computer-Assisted Cognitive 
Remediation both improved selected cognitive skills, and the Think Program reduced emergency room 
visits for mental health concerns. These approaches may be helpful when used along with antipsychotic 
medications. 
rev iew
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Yet there are psychosocial research implications as well. Most importantly, new trials are needed to expand 
the treatment options. For example, a form of cognitive-behavioural therapy (CBT) shows promise with first-
episode psychosis, according to a recent pilot study in youth aged 14 to 18 years.27 This form of CBT involved 
setting individual goals and helping young people achieve them. Although too few youth were recruited to 
definitively assess the impact, initial findings suggested that CBT may reduce psychotic symptoms.27 Further 
evaluation of CBT is therefore warranted.28 Expanding the psychosocial treatment options for youth with 
psychosis is particularly important given the severe side effects of antipsychotic medications. 
Implications for practice and policy
The results of this systematic review suggest three implications for practice and policy.
•  Ensure careful assessment and diagnosis. Some causes of psychosis, such as substance use, are 
reversible. Some causes, such as seizures or infections, are also treatable. So a first step is always to ascertain 
what is causing the presenting problem. Diagnosis can then guide treatment planning, for example, 
considering whether longer-term antipsychotic medications are needed, as in the case of schizophrenia. 
After the diagnosis has been established, ongoing monitoring is also crucial — to assess a youth’s 
symptoms, functioning and response to treatment, including any adverse effects.
•  Use antipsychotic medications carefully. Antipsychotics are a mainstay in treating psychosis in young 
people — both short and long term. Aripiprazole and olanzapine stood out in this review, with two RCTs 
for each medication showing benefits in young people. Yet adverse events were common and severe, so 
both choice of medication and dosing need to be carefully monitored to ensure that benefits outweigh 
harms. Canadian guidelines address monitoring for aripiprazole and olanzapine as well as some of the 
other medications included in this review. These guidelines need to be closely followed for any youth who 
is prescribed antipsychotics.
•  Offer psychosocial interventions as well. Some youth with psychosis will have challenges that 
antipsychotics do not address and may benefit from psychosocial interventions. The three psychosocial 
programs we identified — Cognitive Remediation Therapy, Computer-Assisted Cognitive Remediation 
and the Think Program — showed modest benefits. However, as noted in the Overview, 
a meta-analysis of early psychosis intervention (EPI) programs found that they produced 
very important benefits, including reduced hospitalizations and psychotic symptoms. EPI 
programs typically included a range of psychosocial interventions, such as CBT, social 
skills training and family interventions.14 Therefore EPI programs should be offered to all 
youth with psychosis. As well, new research would help to better understand the differential 
effects of the components of EPI programs — leading to more and better treatment options 
in future.
Psychosis can cause great distress, concerning symptoms and substantial costs for young people and 
their families and communities — including the costs of lost human potential when healthy development is 
interrupted.29 Research shows that interventions can mitigate the distress and symptoms, particularly if young 
people receive these early in the course of the disorder. Antipsychotic medications are a mainstay of treatment, 
albeit with careful monitoring given their side effects, as are EPI programs. Meanwhile, new psychosocial 
treatments are also emerging. Early interventions can help young people with psychosis return to healthy 
development and functioning — and return to flourishing.
rev iew
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people with psychosis 
return to healthy 
development and 
functioning.
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We use systematic review methods adapted from the Cochrane Collaboration and Evidence-Based Mental Health. We build quality assessment into our inclusion criteria to ensure that we report on the best available research evidence — requiring that intervention studies use randomized 
controlled trials (RCTs) and meet additional quality indicators. For this review, we searched for RCTs on 
effective interventions for treating psychosis. Table 7 outlines our database search strategy.
m e t h o d s
To identify additional RCTs, we also hand-searched the Web of Science database, reference lists from 
relevant published systematic reviews and previous issues of the Quarterly. Using this approach, we identified 
42 studies. Two team members then independently assessed each study, applying the inclusion criteria 
outlined in Table 8. 
Eight RCTs met all the inclusion criteria. Figure 1 depicts our search process, adapted from Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses. Data from these studies were then extracted, 
summarized and verified by two or more team members. Throughout our process, any differences between 
team members were resolved by consensus.
For more information on our research methods, please contact
Jen Barican, chpc_quarterly@sfu.ca 
Children’s Health Policy Centre, Faculty of Health Sciences  
Simon Fraser University, Room 2435, 515 West Hastings St. Vancouver, BC  V6B 5K3 
•	 CINAHL,	ERIC,	Medline	and	PsycINFO







Table 7: Search Strategy
















head-to-head comparison trials were only accepted if at least one medication was already established 
as being effective in a placebo-controlled RCT with young people
•	 Double-blinding	procedures	were	used
* We defined inappropriate analysis as not controlling for multiple comparisons or variables that might influence outcomes.
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Records identified through  
database searching
(n = 1,235)









(n = 34 studies
[63 articles])
Total records screened (n = 1,251)




(n = 42 studies [76 articles])
Studies included in review
(n = 8 RCTs [13 articles])
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Practitioners and policy-makers need good evidence about whether a given intervention works to help children. Randomized controlled trials (RCTs) are the gold standard for assessing whether an intervention is effective. In RCTs, children, youth or families are randomly assigned to the intervention 
group or to a comparison or control group. By randomizing participants — that is, by giving every young 
person an equal likelihood of being assigned to a given group — researchers can help ensure the only 
difference between the groups is the intervention. This process provides confidence that benefits are due to the 
intervention rather than to chance or other factors. 
The highest standard for assessing medication effectiveness and safety involves RCTs designed so 
that control youth receive a placebo and so that youth and assessors are blinded regarding who is in the 
intervention and who is in the control groups. All medication RCTs were also double-blinded so neither 
youth nor researchers knew which group young people were assigned to — whether it was a head-to-head 
medication trial or a placebo control trial. This approach is typical for medication studies; it helps to ensure 
that beliefs about the potential effectiveness of the intervention do not influence outcomes.
To determine whether the intervention actually provides benefits, researchers analyze relevant outcomes. 
If an outcome is found to be statistically significant, it helps provide certainty the intervention was effective 
rather than results appearing that way due to chance. In the studies we reviewed, researchers used the typical 
convention of having at least 95% confidence that the observed results actually reflected the program’s real 
impact. 
As well, several studies included in this issue also calculated effect sizes, which described the degree 
of clinically meaningful difference the intervention made in young people’s lives. The studies reported on 
Cohen’s d, which can range from 0 to 2. Standard interpretations are 0.2 = small effect; 0.5 = medium effect; 
and 0.8 = large effect.  
Effect sizes describe the degree of clinically meaningful difference the intervention made in young people’s lives.
r e s e a r c h t e r m s e x p l a i n e d
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r e f e r e n c e s
BC government staff can access original articles from BC’s Health and Human Services Library. Articles 
marked with an asterisk (*) include randomized controlled trial data that was featured in our Review article.
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